Please login to the form below

Not currently logged in
Email:
Password:

Arrowhead Therapeutics

This page shows the latest Arrowhead Therapeutics news and features for those working in and with pharma, biotech and healthcare.

Amgen takes aim at cardio diseases with Arrowhead RNAi deal

Amgen takes aim at cardio diseases with Arrowhead RNAi deal

Amgen has bolstered its cardiovascular pipeline by licensing two gene silencing therapies developed by Arrowhead Therapeutics in a deal valued at up to $670m. ... RNA interference (RNAi) specialist Arrowhead pockets $56.5m upfront with another $617m in

Latest news

  • Oncology bias in pharma deals

    Through this deal,  Arrowhead is now a fully integrated RNAi therapeutics developer with three primary siRNA formats. ... disease) to Newron Pharmaceuticals, triggered the termination of Biotie Therapeutics' acquisition of Newron.

More from news
Approximately 1 fully matching, plus 1 partially matching documents found.

Latest Intelligence

  • Pharma deals during December 2012 Pharma deals during December 2012

    cancer. Finally whilst in California it should be mentioned that Shire has closed a $32.8m research and licence agreement with Arrowhead for research of peptide-targeted therapeutics for rare diseases. ... Commercial deals bring an early Christmas to

More from intelligence
Approximately 0 fully matching, plus 1 partially matching documents found.

PMEA Awards 2020

COVID-19 Updates and Daily News

Featured jobs

PMHub

Add my company
TRIDUCIVE

Triducive are a strategic healthcare consultancy who produce communications that have practical, dynamic application that encourage behaviour change because of the...

Latest intelligence

4 ways to recruit Alzheimer’s disease patients for your clinical trial
What key things do you need to remember to reach patients living with Alzheimer’s disease?...
competitive intelligence
Integrating competitive intelligence into business development, licensing and M&A strategy
The advantages of partnering with a competitive intelligence or knowledge management team...
reaching HCPs during pandemic
Reaching patients and HCPs during the pandemic
COVID-19 has caused unprecedented disruption to drug launches, but some pharma companies avoided costly delays by quickly pivoting to digital channels...

Infographics